Fermentalg: Record Revenue of €3.7 Million in Q1 2026
Fermentalg achieved a revenue of €3.7 million in the first quarter of 2026, surpassing the previous record from early 2025 (€3.6 million). This performance is based on a strategic realignment: the company temporarily shifted away from the aquaculture segment, which accounted for over a quarter of its revenue a year earlier, to focus on higher value-added segments. This commercial adjustment creates a central tension: demonstrating immediate growth by sacrificing volume, while aiming to reach the 2026 target (€20 million) based on the launch of two major innovations in the second half of the year.
42% Growth Excluding Aquaculture, Temporary Suspension of Low-Margin Segment
Sales from the ΩRIGINS™ lipid range intended for dietary supplements and infant nutrition increased by 42% year-over-year: from €2.6 million in the first quarter of 2025 to €3.7 million in the first quarter of 2026. This acceleration occurred after the company temporarily moved away from the aquaculture segment, which had generated €1.0 million in revenue in the first quarter of 2025 and was characterized by low margins. Fermentalg describes this reorientation as 'temporary', emphasizing that the company shifted away from this segment due to its profitability characteristics. The record revenue at the start of this year thus reflects the strategy outlined during the 2025 annual results: accelerating growth by focusing on higher-margin segments rather than on massive but less profitable volumes.
Recovery in Fish Oil Prices and Substitution Window
Beyond portfolio adjustments, Fermentalg observes a favorable macroeconomic evolution for its BioSolutions. After a challenging end to 2024 (fish oil prices divided by three), a stabilization in 2025 is followed by a significant increase in fish oil prices in the first quarter of 2026. This rise in fish prices is attributed to a drastic reduction in fishing quotas, lower yields, and sustained demand for high omega-3 concentration products. Fermentalg deduces that the economic competitiveness of its algae solutions is gradually being restored, facilitating the transition for agri-food industry players and creating potential growth leverage in the second half of 2026. This dynamic could allow the company to revisit the aquaculture segment by the end of the year.
EPA/DHA ΩRIGINS™ and Galdieria Blue: Industrial Launches Completed
Fermentalg has finalized the technological developments of its two major innovations and delivered the first industrial batches to commercial partners. The new EPA/DHA ΩRIGINS™ range is presented as an alternative to fish oils, offering equivalent composition and nutritional benefits. The natural blue dye Galdieria Blue™ has received FDA approval in the US and a favorable opinion from the European Food Safety Authority (EFSA) in March 2026, paving the way for its marketing authorization in Europe. The commercial impact of these two launches is expected in the second half of 2026. Based on these timelines and observed market developments, Fermentalg reaffirms its ambition to achieve €20 million in revenue in 2026 and anticipates a strong acceleration of its growth in the second half of the year.
